Volasertib preclinical activity in high-risk hepatoblastoma
Dina Kats(Children's Cancer Therapy Development Institute), Charles Keller(University of Utah)
Cited by 31
Related Papers
Alveolar rhabdomyosarcomas in conditional <i>Pax3:Fkhr</i> mice: cooperativity of Ink4a/ARF and Trp53 loss of function
|Genes & Development|2004|299
Lineage of origin in rhabdomyosarcoma informs pharmacological response
|Genes & Development|2014|104
Cell-Cycle Dependent Expression of a Translocation-Mediated Fusion Oncogene Mediates Checkpoint Adaptation in Rhabdomyosarcoma
|PLoS Genetics|2014|46
Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma
|BMC Cancer|2019|19
Non-chemotherapy adjuvant agents in TP53 mutant Ewing sarcoma
|Scientific Reports|2023|4